Effect of selenium supplementation in treatment of patients candidate for coronary artery bypass grafting

Clinical trial of the effect of selenium supplementation compared with the placebo on metabolic profiles in patients candidate for coronary artery bypass grafting

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017090533941N22

Enrollment

Registered

2017-11-12

Start date

2017-10-23

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Heart Disease. Chronic ischaemic heart disease, unspecified

Interventions

Intervention 1: Intervention group: selenium tablet (Webber Naturals, Mississauga, Canada), 200 µg, daily, for 4 weeks orally. Intervention 2: Control group: placebo tablet (Barij Essence, Kashan, Ira

Eligibility

Sex/Gender

All

Age

40 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients candidate for coronary artery bypass grafting

Exclusion criteria

Exclusion criteria: Consuming selenium supplements within the last 3 months Having cardiac surgery within the past 3 months Significant renal of hepatic failure Change in the dosage and kind of medications

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Insulin. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Elisa kit.	—

Secondary

Measure	Time frame
Malondialdehyde. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Elisa kit.;Total cholesterol. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;Nitric oxide. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;LDL-cholesterol. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.	—

Measure

Time frame

Malondialdehyde. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Elisa kit.;Total cholesterol. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;Nitric oxide. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.;LDL-cholesterol. Timepoint: At the beginning of the study and after 4 weeks of intervention. Method of measurement: Enzymatic kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 4, 2026